

*Electronic Supplementary Information*

**A Convenient Approach to Acyclic Unsaturated Amino Acids via  
Ring-Closing Metathesis**

Hani Mutlak A. Hassan<sup>\*‡</sup> and Fraser K. Brown

**Contents:**

General Experimental.....	S2
Experimental for Synthesized Compounds.....	S3-S14
<sup>1</sup> H and <sup>13</sup> C NMR Spectra.....	S15-S37
References.....	S38

---

*Manchester Interdisciplinary Biocentre (MIB), University of Manchester, 131 Princess Street, Manchester, M1 7DN, UK.*

‡ Current address: Department of Chemistry, University of Sheffield, Brook Hill, Sheffield, S3 7HF, UK.  
E-mail: h.hassan@sheffield.ac.uk.

## General Experimental.


Unless otherwise noted, all air and moisture sensitive reactions were carried out under a positive pressure of nitrogen atmosphere in oven-dried glassware using anhydrous solvents. Reagents were purchased from commercial sources and used without further purification. Reactions were magnetically stirred and examined by thin layer chromatography (TLC) using ultraviolet light (254 nm) and/or aqueous potassium permanganate solution for visualization. All lactams, macrolactam, unsaturated amino acids, and unsaturated amino esters were treated as light sensitive.

$^1\text{H}$  and  $^{13}\text{C}$  nuclear magnetic resonance (NMR) spectra were recorded on Bruker DPX-300 or 400 instruments. Chemical shifts are reported in parts per million (ppm) relative to chloroform ( $\delta$  7.26) or methanol ( $\delta$  3.31) for  $^1\text{H}$  NMR and chloroform ( $\delta$  77.0) for  $^{13}\text{C}$  NMR. Multiplicities and other abbreviations are expressed as follows: singlet (s), doublet (d), triplet (t), quartet (q), quintet (qu), multiplet (m), broad (br), and apparent (app). Coupling constants are recorded in Hertz (Hz). High resolution mass spectrometry fast atom bombardment (HRMS FAB) was conducted using a Kratos MS50TC instrument. All microwave-based reactions were carried out using CEM Discover Microwave Synthesizer with Explorer Carousel.

## Experimental.

### ***N*-allylpent-4-enamide (3a):<sup>1</sup>**

To a MW reaction tube was added allylamine **1** (732  $\mu$ L, 9.78 mmol) and 4-pentenoic acid **2a** (1 mL, 9.78 mmol). The tube was sealed and placed in the MW reactor (300 W,




150  $^{\circ}$ C, 250 psi pressure, 30 min with continuous stirring while cooling the vessel) in solvent-free conditions. Purification by silica gel column chromatography (25% EtOAc in  $\text{CH}_2\text{Cl}_2$ ) afforded 1.30

g (96%) of **3a** as a yellow oil (TLC:  $R_f$  = 0.49):  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  6.62 (br s, 1H) 5.75–5.67 (m, 2H), 5.11–4.89 (m, 4H), 3.79–3.75 (m, 2H), 2.31–2.20 (m, 4H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  172.3, 136.9, 134.1, 115.8, 115.2, 41.6, 35.4, 29.4; HRMS (FAB) calcd for  $\text{C}_8\text{H}_{13}\text{NO}$  ( $\text{MNa}^+$ ) 162.0889, found 162.0887.

### ***N*-allyl-3-methylpent-4-enamide (3b):**

Experimental procedure for **3a** was followed, with allylamine **1** (925  $\mu$ L, 12.36 mmol) and 3-methyl-4-pentenoic acid **2b** (1 mL, 8.24 mmol). Purification by silica gel column




chromatography (10% EtOAc in  $\text{CH}_2\text{Cl}_2$ ) afforded 1.25 g (99%) of **3b** (TLC:  $R_f$  = 0.42) as a pale yellow oil:  $^1\text{H}$  NMR (300 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  6.57 (br s, 1H), 5.75–5.64 (m, 2H), 5.12–4.86 (m,

4H), 3.78 (m, 2H), 2.66–2.58 (m, 1H), 2.19 (dd,  $J$  = 15.0, 9.0 Hz, 1H), 2.08 (dd,  $J$  = 15.0, 9.0 Hz, 1H), 0.97 (d,  $J$  = 6.6 Hz, 3H);  $^{13}\text{C}$  NMR (75 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  171.9, 142.6, 134.2, 115.8, 113.1, 43.3, 41.6, 34.5, 19.4; HRMS (FAB) calcd for  $\text{C}_9\text{H}_{15}\text{NO}$  ( $\text{MNa}^+$ ) 176.1045, found 176.1040.

### **N-allyl-3,3-dimethylpent-4-enamide (3c):**

Experimental procedure for **3a** was followed, with allylamine **1** (1.12 mL, 15.0 mmol) and 3,3-methyl-4-pentenoic acid **2c** (960 mg, 7.5 mmol). Purification by silica gel




column chromatography (10% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) afforded 784 mg (63%) of **3c** as a yellow oil (TLC: *R<sub>f</sub>* = 0.27): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm) δ 5.91 (dd, *J* = 17.2, 10.8 Hz, 1H), 5.85–5.76 (m, 1H),

5.61 (br s, 1H), 5.16 (dd, *J* = 17.2, 1.2 Hz, 1H), 5.10 (dd, *J* = 10.8, 1.2 Hz, 1H), 5.01 (dd, A<sub>2</sub>X system, *J* = 17.2, 10.8 Hz, 2H), 3.84 (t, *J* = 5.6 Hz, 2H), 2.20 (s, 2H), 1.13 (s, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, ppm) δ 170.8, 147.2, 134.3, 116.1, 111.4, 49.3, 41.7, 36.2, 26.9 (2 C); HRMS (FAB) calcd for C<sub>9</sub>H<sub>15</sub>NO (MNa<sup>+</sup>) 190.1202, found 190.1201.

### **N-allyl-4-methylpent-4-enamide (3d):**

Experimental procedure for **3a** was followed, with allylamine **1** (329 μL, 4.39 mmol) and ethyl-4-methyl-4-pentenoate **2d** (700 μL, 4.39 mmol). Purification by silica gel column




chromatography (10% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) afforded 391 mg of **3d** (58%) as a yellow oil (TLC: *R<sub>f</sub>* = 0.23): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm) δ 6.69 (br s, 1H), 5.77–5.68 (m, 1H), 5.07 (d, *J* = 17.2

Hz, 1H), 5.00 (d, *J* = 10.0, 1H), 4.65 (s, 1H), 4.60 (s, 1H), 3.76 (m, 2H), 2.31–2.22 (m, 4H), 1.64 (s, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, ppm) δ 172.6, 144.2, 134.1, 115.7, 110.1, 41.6, 34.4, 33.1, 22.2; HRMS (FAB) calcd for C<sub>9</sub>H<sub>15</sub>NO (MNa<sup>+</sup>) 176.1045, found 176.1047.

### ***N*-allylhex-5-enamide (3e):**

Experimental procedure for **3a** was followed, with allylamine **1** (315  $\mu$ L, 4.21 mmol) and 5-hexenoic acid **2e** (500  $\mu$ L, 4.21 mmol). Purification by silica gel column



chromatography (8% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) afforded 586 mg (91%)

of **3e** as a pale yellow oil (TLC:  $R_f$  = 0.32): <sup>1</sup>H NMR (300 MHz,

CDCl<sub>3</sub>, ppm)  $\delta$  6.52 (br s, 1H), 5.77–5.63 (m, 2H), 5.11–4.87 (m,


4H), 3.79–3.75 (m, 2H), 2.15 (t,  $J$  = 7.8 Hz, 2H), 2.04–1.97 (m, 2H), 1.66 (qu,  $J$  = 7.8 Hz,

2H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, ppm)  $\delta$  172.9, 137.7, 134.1, 115.8, 114.9, 41.6, 35.5,

32.9, 24.6; HRMS (FAB) calcd for C<sub>9</sub>H<sub>15</sub>NO (MNa<sup>+</sup>) 176.1045, found 176.1045.

### ***Tert*-butyl-allylpent-4-enoylcarbamate (4a):<sup>2</sup>**

To an oven-dried round-bottomed flask was added *N*-allylpent-4-enamide **3a** (1.23 g, 8.85 mmol), Boc<sub>2</sub>O (3.858 g, 17.7 mmol; added as liquid), DMAP (432 mg, 3.54 mmol),



and CH<sub>3</sub>CN (8 mL). The 1 M reaction mixture was stirred at rt for

2 h, under nitrogen atmosphere. The resulting deep red reaction

mixture was concentrated *in vacuo* to give a deep red oil.

Purification by silica gel column chromatography (3:10:87, Et<sub>3</sub>N/EtOAc/hexane)

afforded 2.11 g of **4a** (100%) as a yellow oil (TLC:  $R_f$  = 0.76): <sup>1</sup>H NMR (300 MHz,

CDCl<sub>3</sub>, ppm)  $\delta$  5.81–5.67 (m, 2H), 5.09–4.90 (m, 4H), 4.23 (d,  $J$  = 5.7 Hz, 2H), 2.92 (t,  $J$


= 7.8 Hz, 2H), 2.37–2.30 (m, 2H), 1.45 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, ppm)  $\delta$

174.7, 152.8, 137.3, 133.4, 116.2, 114.9, 82.7, 46.3, 37.4, 28.9, 27.8 (3 C); HRMS (FAB)

calcd for C<sub>13</sub>H<sub>21</sub>NO<sub>3</sub> (MNa<sup>+</sup>) 262.1413, found 262.1408.

### **Tert-butyl-3-methylpent-4-enoylallylcarbamate (4b).**

Experimental procedure for **4a** was followed, with *N*-allyl-3-methylpent-4-enamide **3b** (200 mg, 1.31 mmol), Boc<sub>2</sub>O (685 mg, 3.14 mmol), DMAP (64 mg, 0.524 mmol), and




CH<sub>3</sub>CN (1 mL). Purification by silica gel column chromatography (3:10:87, Et<sub>3</sub>N/EtOAc/hexane) afforded 320 mg of **4b** (97%) as a

yellow oil (TLC: *R<sub>f</sub>* = 0.70): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, ppm) δ 5.84–5.70 (m, 2H), 5.12–4.89 (m, 4H), 4.25 (d, *J* = 5.7 Hz, 2H), 2.95–2.69 (m, 3H), 1.48 (s, 9H), 1.03 (d, *J* = 6.3 Hz, 3H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, ppm) δ 174.3, 152.9, 143.1, 133.5, 116.3, 112.9, 82.8, 46.4, 44.7, 34.1, 27.9 (3 C), 19.7; HRMS (FAB) calcd for C<sub>14</sub>H<sub>23</sub>NO<sub>3</sub> (MNa<sup>+</sup>) 276.1570, found 276.1568.

### **Tert-butyl-3,3-dimethylpent-4-enoylallylcarbamate (4c):**

Experimental procedure for **4a** was followed, with *N*-allyl-3,3-dimethylpent-4-enamide **3c** (714 mg, 4.27 mmol), Boc<sub>2</sub>O (2.33 g, 10.67 mmol), DMAP (260 mg, 2.13 mmol), and




CH<sub>3</sub>CN (4 mL). Purification by silica gel column chromatography (3:10:87, Et<sub>3</sub>N/EtOAc/hexane) afforded 915 mg of **4c** (80%) as a

yellow oil (TLC: *R<sub>f</sub>* = 0.76): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm) δ 5.94 (dd, *J* = 17.2, 10.8 Hz, 1H), 5.82–5.75 (m, 1H), 5.14–5.07 (m, 2H), 4.95–4.89 (m, 2H), 4.23 (d, *J* = 5.6 Hz, 2H), 2.97 (s, 2H), 1.49 (s, 9H), 1.12 (s, 6H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, ppm) δ 173.6, 153.2, 147.3, 133.6, 116.4, 110.4, 82.7, 48.5, 46.5, 36.8, 27.9 (3 C), 27.1 (2 C); HRMS (FAB) calcd for C<sub>15</sub>H<sub>25</sub>NO<sub>3</sub> (MNa<sup>+</sup>) 290.1726, found 290.1725.

### **Tert-butyl-4-methylpent-4-enoylallylcarbamate (4d):**

Experimental procedure for **4a** was followed, with *N*-allyl-4-methylpent-4-enamide **3d** (198 mg, 1.29 mmol), Boc<sub>2</sub>O (676 mg, 3.10 mmol), DMAP (63 mg, 0.516 mmol), and




CH<sub>3</sub>CN (1 mL). Purification by silica gel column chromatography (3:8:89, Et<sub>3</sub>N/EtOAc/hexane) afforded 311 mg of **4d** (95%) as a

yellow oil (TLC:  $R_f = 0.71$ ): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm) δ 5.81–5.72 (m, 1H), 5.11–5.06 (m, 2H), 4.70 (s, 1H), 4.66 (s, 1H), 4.25 (d,  $J = 5.6$  Hz, 2H), 2.98 (t,  $J = 8.0$  Hz, 2H), 2.31 (t,  $J = 8.0$  Hz, 2H), 1.72 (s, 3H), 1.48 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, ppm) δ 175.1, 152.8, 144.6, 133.4, 116.3, 109.9, 82.8, 46.4, 36.5, 32.7, 27.9 (3 C), 22.6; HRMS (FAB) calcd for C<sub>14</sub>H<sub>23</sub>NO<sub>3</sub> (MNa<sup>+</sup>) 276.1570, found 276.1564.

### **Tert-butyl-allylhex-5-enoylcarbamate (4e):**

Experimental procedure for **4a** was followed, with *N*-allylhex-5-enamide **3e** (360 mg, 2.35 mmol), Boc<sub>2</sub>O (1.229 g, 5.64 mmol), DMAP (115 mg, 0.94 mmol), and CH<sub>3</sub>CN (2




mL). Purification by silica gel column chromatography (3:10:87, Et<sub>3</sub>N/EtOAc/hexane) afforded 565 mg of **4e** (95%) as a yellow oil (TLC:  $R_f = 0.71$ ): <sup>1</sup>H NMR (300 MHz, CDCl<sub>3</sub>, ppm) δ 5.82–5.71

(m, 2H), 5.06–4.92 (m, 4H), 4.25 (d,  $J = 5.7$  Hz, 2H), 2.84 (t,  $J = 7.5$  Hz, 2H), 2.11–2.04 (m, 2H), 1.72 (qu,  $J = 7.5$ , 2H), 1.48 (s, 9H); <sup>13</sup>C NMR (75 MHz, CDCl<sub>3</sub>, ppm) δ 175.4, 152.9, 138.1, 133.4, 116.2, 114.9, 82.8, 46.4, 37.5, 33.1, 27.9 (3 C), 24.2; HRMS (FAB) calcd for C<sub>14</sub>H<sub>23</sub>NO<sub>3</sub> (MNa<sup>+</sup>) 276.1570, found 276.1567.

**(Z)-tert-butyl-3,4-dihydro-2-oxo-2H-azepine-1(7H)-carboxylate (5a):<sup>2</sup>**

To an oven-dried round-bottomed flask fitted with a condenser was added *tert*-butylallylpent-4-enoylcarbamate **4a** (100 mg, 4.18 mmol) and deoxygenated CH<sub>2</sub>Cl<sub>2</sub> (418




mL). Grubbs' second-generation ruthenium catalyst **A** (18 mg, 2.09 mmol, 5 mol %) was then added in one aliquot. The 1 mM reaction mixture was

heated to reflux (50 °C) with stirring for 24 h in the absence of light, under a stream of nitrogen atmosphere. Following removal of the solvent, Ru scavenger (SiO<sub>2</sub>-Si(CH<sub>2</sub>)<sub>3</sub>NH<sub>2</sub>,<sup>3</sup> 10 equiv w/w relative to catalyst) and hexane (10 mL) were added and the resulting mixture was stirred vigorously at rt for 2 h. The crude product was passed through a pad of silica gel (100 mg per approximately 100 mg crude product) using a fritted filtration column, eluting with 3% Et<sub>3</sub>N in hexane (20 mL) and further with 3:10:87 Et<sub>3</sub>N/EtOAc/hexane (10 mL). The filtrate was then concentrated to dryness to obtain 85 mg (97%) of **5a** as a yellow oil without the need for further purification: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm) δ 5.85–5.74 (m, 2H), 4.34–4.32 (m, 2H), 2.87 (t, *J* = 6.4 Hz, 2H), 2.48 (m, 2H), 1.52 (s, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, ppm) δ 174.2, 152.2, 131.7, 124.3, 82.8, 41.9, 36.1, 27.9 (3 C), 25.6; HRMS (FAB) calcd for C<sub>11</sub>H<sub>17</sub>NO<sub>3</sub> (MNa<sup>+</sup>) 234.1101, found 234.1102.

**(Z)-tert-butyl-3,4-dihydro-4-methyl-2-oxo-2H-azepine-1(7H)-carboxylate (5b):**

Experimental procedure for **5a** was followed, with *tert*-butyl-3-methylpent-4-



enoylallylcarbamate **4b** (108 mg, 0.426 mmol), Grubbs' second-generation ruthenium catalyst **A** (18 mg, 0.0213 mmol, 5 mol %), and deoxygenated

CH<sub>2</sub>Cl<sub>2</sub> (427 mL). The crude product **5b** was obtained as a yellow oil (87 mg, 91%)




without the need for further purification:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  5.75 (ddd,  $J$  = 11.2, 6.0, 1.6 Hz, 1H), 5.64 (dd,  $J$  = 11.2, 3.2 Hz, 1H), 4.29 (m, 2H), 2.83–2.73 (m, 2H), 2.67 (m, 1H), 1.51 (s, 9H), 1.12 (d,  $J$  = 7.2 Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  173.1, 152.1, 137.8, 123.0, 82.9, 43.3, 41.9, 31.5, 27.9 (3 C), 21.5; HRMS (FAB) calcd for  $\text{C}_{12}\text{H}_{19}\text{NO}_3$  ( $\text{MNa}^+$ ) 248.1257, found 248.1257.

**(Z)-tert-butyl-3,4-dihydro-4,4-dimethyl-2-oxo-2H-azepine-1(7H)-carboxylate**

**(5c):**

Experimental procedure for **5a** was followed, with *tert*-butyl 3,3-dimethylpent-4-enoylallylcarbamate **4c** (107 mg, 0.40 mmol), Grubbs' second-generation ruthenium




catalyst **A** (17 mg, 0.02 mmol, 5 mol %), and deoxygenated  $\text{CH}_2\text{Cl}_2$  (400 mL). The crude product **5c** was obtained as a yellow oil (94 mg, 98%)

without the need for further purification:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , ppm): 5.65 (dt,  $J$  = 11.2, 6.0 Hz, 1H), 5.50 (d,  $J$  = 11.2 Hz, 1H), 4.26 (d,  $J$  = 6.0 Hz, 2H), 2.72 (s, 2H), 1.49 (s, 9H), 1.09 (s, 6H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , ppm): 172.4, 152.1, 142.4, 121.1, 82.9, 49.1, 41.9, 35.2, 29.7 (2 C), 27.9 (3 C); HRMS (FAB) calcd for  $\text{C}_{13}\text{H}_{21}\text{NO}_3$  ( $\text{MNa}^+$ ) 262.1413, found 262.1411.

**Macrolactam 6a:**

Experimental procedure for **5a** was followed, with *tert*-butyl-allylpent-4-enoylcarbamate




**4a** (200 mg, 0.836 mmol), Grubbs' second-generation ruthenium catalyst **A** (35 mg, 0.0418 mmol, 5 mol %), and deoxygenated  $\text{CH}_2\text{Cl}_2$  (21 mL). Reaction mixture concentration

= 40 mM. Ru scavenger ( $\text{SiO}_2\text{-Si}(\text{CH}_2)_3\text{NH}_2$ , 20 equiv w/w relative to catalyst) was used for catalyst byproducts removal and a pad of silica gel (200 mg per approximately 100 mg crude product) was used to pass the crude product through, eluting with 3%  $\text{Et}_3\text{N}$  in hexane (40 mL) and further with 3:10:87  $\text{Et}_3\text{N}/\text{EtOAc}/\text{hexane}$  (20 mL). Purification by silica gel column chromatography (3%  $\text{Et}_3\text{N}$  in hexane) afforded 94 mg of **6a** (53%) as a colourless oil, which crystallized overtime to give a white solid (TLC:  $R_f = 0.15$ ):  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  5.53–5.29 (m, 4H, 2  $\text{CH}=\text{CH}$ ), 4.22 (m, 4H), 2.86–2.82 (m, 4H), 2.33 (m, 4H), 1.52 (s, 18H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , ppm; presence of rotamers)  $\delta$  174.4, 174.2, 153.3, 153.1, 131.3, 129.2, 127.8, 125.8, 82.9, 82.8, 45.8, 45.5, 37.4, 37.2, 28.0 (6 C), 27.6, 27.4; HRMS (FAB) calcd for  $\text{C}_{22}\text{H}_{34}\text{N}_2\text{O}_6$  ( $\text{MNa}^+$ ) 445.2309, found 445.2305.

**(Z)-6-(tert-butoxycarbonyl)-hex-4-enoic acid (7a):**

2 M 1:1 LiOH in THF/ $\text{H}_2\text{O}$  ( $220 \mu\text{L} \times 2$ ) were independently added to lactam **5a** (33 mg, 0.156 mmol). The 0.35 M biphasic reaction mixture was stirred at 30 °C for 2 h in the absence of light. Water (2 mL) was added and the crude product was extracted with EtOAc (5 mL). The pH of the aqueous phase was acidified by a dropwise addition of 1 M HCl. The crude




product was extracted three times with EtOAc (10 mL) and further with  $\text{CH}_2\text{Cl}_2$  (10 mL). The combined organic layers were dried ( $\text{MgSO}_4$ ), filtered, and the solvent was evaporated *in vacuo* to give a yellow oil. Purification by silica gel column chromatography (6%  $\text{CH}_3\text{OH}$  in  $\text{CH}_2\text{Cl}_2$ ) afforded 35 mg of **7a** (97%) as a yellow oil (TLC:  $R_f = 0.17$ ):  $^1\text{H}$  NMR (400 MHz,  $\text{CD}_3\text{OD}$ , ppm)  $\delta$  5.49–5.39 (m, 2H), 3.70 (d,  $J =$

6.0 Hz, 2H), 2.37 (m, 4H), 1.43 (s, 9H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  178.1, 155.9, 130.3, 127.5, 79.4, 37.4, 33.7, 28.3 (3 C), 22.4; HRMS (FAB) calcd for  $\text{C}_{11}\text{H}_{19}\text{NO}_4$  ( $\text{MH}^+$ ) 230.1387, found 230.1392.

**(Z)-6-(tert-butoxycarbonyl)-3-methylhex-4-enoic acid (7b).**

Experimental procedure for **7a** was followed, with lactam **5b** (55 mg, 0.244 mmol) and 2 M 1:1 LiOH in THF/ $\text{H}_2\text{O}$  ( $350\ \mu\text{L} \times 2$ ). Purification by silica gel column chromatography




(6%  $\text{CH}_3\text{OH}$  in  $\text{CH}_2\text{Cl}_2$ ) afforded 55 mg of **7b** (93%) as a colourless oil (TLC:  $R_f = 0.24$ ):  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  5.39 (dt,  $J = 10.8, 6.8$  Hz, 1H), 5.28 (app t,  $J = 10.4$  Hz, 1H),

4.75 (br s, 1H), 3.76 (m, 2H), 3.03–2.94 (m, 1H), 2.36 (dd,  $J = 15.2, 6.0$  Hz, 1H), 2.25 (dd,  $J = 15.2, 8.8$  Hz, 1H), 1.43 (s, 9H), 1.02 (d,  $J = 6.8$  Hz, 3H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  177.3, 155.9, 136.4, 125.9, 79.4, 41.6, 37.6, 28.8, 28.4 (3 C), 20.9; HRMS (FAB) calcd for  $\text{C}_{12}\text{H}_{21}\text{NO}_4$  ( $\text{MH}^+$ ) 244.1543, found 244.1554.

**(Z)-6-(tert-butoxycarbonyl)-3,3-dimethylhex-4-enoic acid (7c):**

Experimental procedure for **7a** was followed, with lactam **5c** (50 mg, 0.209 mmol) and 2 M 1:1 LiOH in THF/ $\text{H}_2\text{O}$  ( $300\ \mu\text{L} \times 2$ ). The crude product **7c** was obtained as a yellow




oil (50 mg, 93%) without the need for further purification:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  5.47 (d,  $J = 12.0$  Hz, 1H), 5.27 (dt, 12.0, 6.8 Hz, 1H), 4.75 (br s, 1H), 3.89 (m, 2H), 2.43 (s, 2H),

1.44 (s, 9H), 1.26 (s, 6H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  176.5, 155.9, 138.9, 126.8, 79.5, 47.4, 38.5, 35.5, 29.2 (2 C), 28.4 (3 C); HRMS (FAB) calcd for  $\text{C}_{13}\text{H}_{23}\text{NO}_4$  ( $\text{MH}^+$ ) 258.1699, found 258.1692.

**(E)-6-(tert-butoxycarbonyl)hex-4-enoic acid (8a):**

Experimental procedure for **7a** was followed, with macrolactam **6a** (20 mg, 0.047 mmol) and 2 M 1:1 LiOH in THF/ $\text{H}_2\text{O}$  ( $700\ \mu\text{L} \times 2$ ). The product **8a** was obtained as a yellow




oil (20 mg, 93%):  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  5.64–5.57 (m, 1H), 5.54–5.49 (m, 1H), 4.61 (br s, 1H), 3.69 (m, 2H), 2.44–

2.32 (m, 4H), 1.44 (s, 9H);  $^{13}\text{C}$  NMR (100 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  178.1, 155.9, 130.3, 127.5, 79.4, 42.4, 33.7, 28.3 (3 C), 27.1; HRMS (FAB) calcd for  $\text{C}_{11}\text{H}_{19}\text{NO}_4$  ( $\text{MH}^+$ ) 230.1387, found 230.1383.

**(Z)-tert-butyl-5-(ethoxycarbonyl)pent-2-enylcarbamate (9a):**

To lactam **5a** (47 mg, 0.222 mmol) in absolute EtOH ( $634\ \mu\text{L}$ ) at  $0\ ^\circ\text{C}$ , was added  $\text{Cs}_2\text{CO}_3$  (108 mg, 0.333 mmol). The 0.35 M reaction mixture was stirred at  $30\ ^\circ\text{C}$  for 2 h




in the absence of light. EtOH was removed *in vacuo* and the resulting residue was filtered through a short plug of Celite, eluting with  $\text{Et}_2\text{O}$ . The filtrate was concentrated to dryness to

give 57 mg of **9a** (100%) as a yellow oil without the need for further purification:  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ , ppm)  $\delta$  5.52–5.43 (m, 2H), 4.62 (br s, 1H), 4.12 (q,  $J = 7.2\ \text{Hz}$ , 2H), 3.76 (m, 2H), 2.37 (m, 4H), 1.44 (s, 9H), 1.25 (t,  $J = 7.2\ \text{Hz}$ , 3H);  $^{13}\text{C}$  NMR (100

MHz, CDCl<sub>3</sub>, ppm)  $\delta$  172.9, 155.8, 130.6, 127.4, 79.3, 60.4, 37.4, 33.9, 28.4 (3 C), 22.7, 14.2; HRMS (FAB) calcd for C<sub>13</sub>H<sub>23</sub>NO<sub>4</sub> (MNa<sup>+</sup>) 280.1519, found 280.1523.

**(Z)-tert-butyl-5-(ethoxycarbonyl)-4-methylpent-2-enylcarbamate (9b):**

Experimental procedure for **9a** was followed, with lactam **5b** (63 mg, 0.28 mmol), Cs<sub>2</sub>CO<sub>3</sub> (136 mg, 0.42 mmol), and EtOH (800  $\mu$ L). The crude product **9b** was obtained as




a yellow oil (100%, 76 mg) without the need for further purification: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm)  $\delta$  5.39 (dt, *J* = 10.8, 6.8 Hz, 1H), 5.27 (app t, *J* = 10.4 Hz, 1H), 4.69 (br s, 1H),

4.16–4.04 (m, 2H), 3.86–3.68 (m, 2H), 3.06–2.95 (m, 1H), 2.31 (dd, *J* = 15.2, 6.0 Hz, 1H), 2.21 (dd, *J* = 15.2, 8.8 Hz, 1H), 1.43 (s, 9H), 1.22 (t, *J* = 7.2 Hz, 3H), 1.00 (d, *J* = 6.8 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, ppm)  $\delta$  172.4, 155.8, 136.7, 125.7, 79.2, 60.3, 41.8, 37.5, 28.9, 28.4 (3 C), 20.9, 14.2; HRMS (FAB) calcd for C<sub>14</sub>H<sub>25</sub>NO<sub>4</sub> (MNa<sup>+</sup>) 294.1675, found 294.1682.

**(Z)-tert-butyl-5-(ethoxycarbonyl)-4,4-dimethylpent-2-enylcarbamate (9c):**

Experimental procedure for **9a** was followed, with lactam **5c** (30 mg, 0.125 mmol), Cs<sub>2</sub>CO<sub>3</sub> (61 mg, 0.187 mmol), and 1:1 EtOH/CH<sub>2</sub>Cl<sub>2</sub> (180  $\mu$ L  $\times$  2). Purification by silica




gel column chromatography (2% EtOAc in CH<sub>2</sub>Cl<sub>2</sub>) afforded 31 mg of **9c** (86%) as a yellow oil (TLC: *R<sub>f</sub>* = 0.19): <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm)  $\delta$  5.46 (d, *J* = 12.0 Hz, 1H), 5.27 (dt, *J* =

12.0, 6.8 Hz, 1H), 4.68 (br s, 1H), 4.10 (q, *J* = 7.2 Hz, 2H), 3.89 (m, 2H), 2.37 (s, 2H), 1.44 (s, 9H), 1.26–1.23 (m, 9H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, ppm)  $\delta$  171.7, 155.7,

139.3, 126.3, 79.3, 60.1, 47.6, 38.4, 35.8, 29.2 (2 C), 28.4 (3 C), 14.3; HRMS (FAB) calcd for C<sub>15</sub>H<sub>27</sub>NO<sub>4</sub> (MNa<sup>+</sup>) 308.1832, found 308.1829.





**(E)-tert-butyl-5-(ethoxycarbonyl)pent-2-enylcarbamate (10a):**

Experimental procedure for **9a** was followed, with macrolactam **6a** (21 mg, 0.0497 mmol), Cs<sub>2</sub>CO<sub>3</sub> (24 mg, 0.0745 mmol), and EtOH (142 μL). The crude product **10a** was









obtained as a yellow oil (25 mg, 98%) without the need for further purification: <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>, ppm) δ 5.58 (dt, *J* = 15.2, 6.0 Hz, 1H), 5.49 (dt, *J* = 15.2, 5.6 Hz, 1H), 4.52 (br s, 1H), 4.15–4.09 (m, 2H), 3.67 (m, 2H), 2.39–2.28 (m, 4H), 1.43 (s, 9H), 1.24 (t, *J* = 7.2 Hz, 3H); <sup>13</sup>C NMR (100 MHz, CDCl<sub>3</sub>, ppm) δ 173.1, 155.7, 130.5, 127.7, 79.3, 60.3, 42.4, 33.8, 28.4 (3 C), 27.4, 14.2; HRMS (FAB) calcd for C<sub>13</sub>H<sub>23</sub>NO<sub>4</sub> (MNa<sup>+</sup>) 280.1519, found 280.1526.



## **$^1\text{H}$ and $^{13}\text{C}$ NMR Spectra**



































































































---

**References for Supplementary Information**

- (1) F. Gagosz, C. Moutrille and S. Z. Zard, *Org. Lett.*, 2002, **4**, 2707–2709.
- (2) A. Kamimura, K. Tanaka, T. Hayashi and Y. Omata, *Tetrahedron Lett.*, 2006, **47**, 3625–3627.
- (3) K. McEleney, D. P. Allen, A. E. Holliday and C. M. Crudden, *Org. Lett.*, 2006, **8**, 2663–2666.